Home LiteratureArticle Details
PMID: 17210731 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.

The Journal of experimental medicine ·Vol. 204 ·No. 1 ·2007-01-22 ·Pages 49-55

Zhang B, Bowerman NA, Salama JK, Schmidt H, Spiotto MT, Schietinger A, Yu P, Fu YX, Weichselbaum RR, Rowley DA, Kranz DM, Schreiber H

Abstract

Targeting cancer cells, as well as the nonmalignant stromal cells cross-presenting the tumor antigen (Ag), can lead to the complete destruction of well-established solid tumors by adoptively transferred Ag-specific cytotoxic T lymphocytes (CTLs). If, however, cancer cells express only low levels of the Ag, then stromal cells are not destroyed, and the tumor escapes as Ag loss variants. We show that treating well-established tumors expressing low levels of Ag with local irradiation or a chemotherapeutic drug causes sufficient release of Ag to sensitize stromal cells for destruction by CTLs. This was shown directly using high affinity T cell receptor tetramers for visualizing the transient appearance of tumor-specific peptide-MHC complexes on stromal cells. Maximum loading of tumor stroma with cancer Ag occurred 2 d after treatment and coincided with the optimal time for T cell transfer. Under these conditions, tumor rejection was complete. These findings may set the stage for developing rational clinical protocols for combining irradiation or chemotherapy with CTL therapy.

MeSH Terms
Adoptive Transfer Animals Antigen Presentation Antigen-Presenting Cells/immunology Antigens, Neoplasm Antineoplastic Agents/pharmacology Cell Line, Tumor Deoxycytidine/analogs & derivatives,pharmacology Immunization In Vitro Techniques Mice Mice, Inbred C57BL Mice, Knockout Neoplasms, Experimental/drug therapy,immunology,radiotherapy Receptors, Antigen, T-Cell/metabolism Stromal Cells/immunology T-Lymphocytes, Cytotoxic/immunology
Chemicals
Antigens, Neoplasm Antineoplastic Agents Receptors, Antigen, T-Cell Deoxycytidine gemcitabine
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Zhang Bin
Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA. [email protected]
Bowerman Natalie A
Salama Joseph K
Schmidt Hank
Spiotto Michael T
Schietinger Andrea
Yu Ping
Fu Yang-Xin
Weichselbaum Ralph R
Rowley Donald A
Kranz David M
Schreiber Hans
References (29)
29 references, click to expand
  1. Kinetics and thermodynamics of T cell receptor- autoantigen interactions in murine experimental autoimmune encephalomyelitis.
    Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6818-23 PMID: 11391002
  2. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.
    Eur J Immunol. 1993 Nov;23(11):2770-6 PMID: 8223853
  3. Tumor rejection by disturbing tumor stroma cell interactions.
    J Exp Med. 2001 Dec 3;194(11):1549-59 PMID: 11733570
  4. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.
    J Exp Med. 1997 Jul 21;186(2):229-38 PMID: 9221752
  5. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells.
    J Exp Med. 1999 Aug 2;190(3):311-22 PMID: 10430620
  6. Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope.
    Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):735-41 PMID: 10524430
  7. Coupling and cross-presentation.
    Nature. 2005 Mar 3;434(7029):27-8 PMID: 15744280
  8. Cross-presentation by intercellular peptide transfer through gap junctions.
    Nature. 2005 Mar 3;434(7029):83-8 PMID: 15744304
  9. The role of tumor stroma in the interaction between tumor and immune system.
    Curr Opin Immunol. 2005 Apr;17(2):180-6 PMID: 15766679
  10. Immunotherapy and chemotherapy--a practical partnership.
    Nat Rev Cancer. 2005 May;5(5):397-405 PMID: 15864281
  11. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.
    Cancer Immun. 2005;5:8 PMID: 15934727
  12. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
    J Immunol. 2005 Jun 15;174(12):7516-23 PMID: 15944250
  13. Combining radiotherapy and immunotherapy: a revived partnership.
    Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):655-66 PMID: 16199306
  14. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
    J Exp Med. 2005 Dec 19;202(12):1691-701 PMID: 16365148
  15. Adoptive immunotherapy for cancer: building on success.
    Nat Rev Immunol. 2006 May;6(5):383-93 PMID: 16622476
  16. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
    J Exp Med. 2006 May 15;203(5):1259-71 PMID: 16636135
  17. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.
    Hematol Oncol Clin North Am. 2006 Jun;20(3):567-84 PMID: 16762725
  18. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  19. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.
    Cancer Res. 2002 Mar 1;62(5):1462-70 PMID: 11888921
  20. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
    Immunity. 2002 Dec;17(6):737-47 PMID: 12479820
  21. TCRs with high affinity for foreign pMHC show self-reactivity.
    Nat Immunol. 2003 Jan;4(1):55-62 PMID: 12469116
  22. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation.
    Immunity. 2003 Feb;18(2):255-64 PMID: 12594952
  23. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
    J Immunol. 2003 May 15;170(10):4905-13 PMID: 12734333
  24. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
    Clin Cancer Res. 2003 May;9(5):1639-47 PMID: 12738716
  25. Bystander elimination of antigen loss variants in established tumors.
    Nat Med. 2004 Mar;10(3):294-8 PMID: 14981514
  26. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing.
    N Engl J Med. 1986 Dec 25;315(26):1650-9 PMID: 3537791
  27. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen.
    J Exp Med. 1990 Apr 1;171(4):1205-20 PMID: 2324687
  28. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.
    J Exp Med. 1992 Jan 1;175(1):139-46 PMID: 1309851
  29. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
    Nature. 2001 Jun 28;411(6841):1058-64 PMID: 11429607
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
2007-01-22
Epub
2007-00-08
Pages
49-55
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2118433
Subset
IM
Grants
NICHD NIH HHS · T32 HD007009 · United States
NCI NIH HHS · R01 CA022677 · United States
NCI NIH HHS · R21-CA111877 · United States
NCI NIH HHS · R01-CA22677 · United States
NCI NIH HHS · P30 CA014599 · United States
NCI NIH HHS · P01 CA097296 · United States
NCI NIH HHS · CA-14599 · United States
NCI NIH HHS · R01-CA37516 · United States
NICHD NIH HHS · HD 07009 · United States
NCI NIH HHS · R01 CA111423 · United States
NCI NIH HHS · P01-CA97296 · United States
NCI NIH HHS · R01-CA111423 · United States
NCI NIH HHS · R21 CA111877 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]